A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer

NCT07278336 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

207

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: ABBV-901
DRUG: Bevacizumab

Sponsor

AbbVie